SS
ENTA icon

SBI Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

SBI Securities’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46K Buy
+100
New +$1.34K ﹤0.01% 2668
2026
Q1 		– Sell
-1
Closed -$16 – 4066
2025
Q4 		$16 Hold
1
– – ﹤0.01% 3810
2025
Q3 		$12 Buy
+1
New +$8 ﹤0.01% 4005

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SBI Securities's ENTA Position: Q2 2026 in Review

SBI Securities opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 100 shares worth $1.46K. The stake represents ﹤0.01% of the portfolio and ranks #2668 among its holdings. This is a return to the name: SBI Securities previously reported a position in ENTA as recently as Q4 2025.

SBI Securities first reported a position in ENTA in Q3 2025 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • SBI Securities held 100 shares of Enanta Pharmaceuticals worth $1.46K as of Q2 2026.
  • Enanta Pharmaceuticals was a new SBI Securities position in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2668 holding.
  • SBI Securities first reported a position in Enanta Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.